| Literature DB >> 36005434 |
Bo He1,2,3, Fang Zhao1,2,3, Wenxi Yu1,2,3, Yi Li1,2,3, Xiaoyan Wu1,2,3, Zhibing Lu1,2,3.
Abstract
Catheter ablation for persistent atrial fibrillation (PeAF) is particularly challenging, as the clinical outcomes are modest. Pulmonary vein isolation (PVI) plus linear ablation is one of the main strategies for PeAF ablation. Completely durable transmural lesions are difficult to achieve by catheter ablation during mitral isthmus ablation. The ligament of Marshall contains the vein of Marshall (VOM), myocardial tracts and innervation, and serves as arrhythmogenic foci that make it an attractive target in catheter ablation of atrial fibrillation. Additionally, it co-localizes with the mitral isthmus, and may serve as a part of the perimitral isthmus reentrant circuit. Ethanol infusion into the VOM results in rapid ablation of the neighboring myocardium and its innervation. Its incorporation into PVI significantly increases the success rate of mitral isthmus block and the clinical outcome of PeAF ablation.Entities:
Keywords: epicardial connection; ethanol infusion; perimitral flutter; persistent atrial fibrillation; vein of Marshall
Year: 2022 PMID: 36005434 PMCID: PMC9409861 DOI: 10.3390/jcdd9080270
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425
Figure 1Gross photo (A) and histochemical staining (B–E) showing the anatomy of the ligament of Marshall. (B) The CS myocardial sleeve is shown by Masson’s trichrome staining of the CS and VOM, which ends at the valve of Vieussens (VV). No myocardial sleeve is seen in the great cardiac vein (GCV). (C) The nerve (brown staining-arrow) is shown by positive avidin-biotin-peroxidase immunohistochemical staining for tyrosine. (×120). (D) Dual-staining of the nerve bundles of the LOM for DBH (blue) and ChAT (brown) showing that cholinergic nerve fibers are predominant (×5). (E) Hematoxylin-eosin staining showing the tracts of the LOM. Three tracts (arrows) emerging from the LOM are shown by subserial sections, which eventually enter the atrial wall. The last panel shows a section from the lower end of the LOM. The tract inserts into the left atrial wall (arrow) and CS (×10). CS, coronary sinus; ChAT, choline acetyl transferase; DBH, dopamine β-hydroxylase; LAA, left atrial appendage; LAFW, left atrial free wall; LOM, ligament of Marshall; M, myocardium; F, fat; PV, pulmonary vein; VOM, vein of Marshall (reproduced and modified with permission from Kim et al. [15], Chou et al. [16], and Ulphani et al. [17]).
Figure 2Recordings of the potentials of the ligament of Marshall (LOM) in dogs and humans. (A) The catheter position and anatomy of LOM in a dog. (B) Simultaneous recording of surface ECG lead I, II, III, aVR, aVL, aVF, HB, LAA, LSPV, LIPV, LOM1-2, LOM5-6, and LOM9-10 in a dog showing LOM potentials (arrows). (C,D) Vein of Marshall (VOM) venography and LOM potentials recorded with a small catheter (VOMc) placed in the VOM in a patient with persistent atrial fibrillation. The Lasso catheter is positioned in the LSPV. (E,F) Simultaneous recording of surface ECG lead I, II, V1, CS1-2~CS9-10, Lasso1-2~Lasso9-10, and VOM1-2~VOM5-6. During a sinus beat, the left atrium potential (LA) is fused with the LOM potential (E). A premature atrial beat separates the LA and the LOM potentials (F). HB, His bundle electrogram; LAA, left atrial appendage; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; CSc, coronary sinus catheter.
Figure 3Perimitral flutter mediated by VOM epicardial connections in a persistent atrial fibrillation patient undergoing PVI and linear ablation. (A) Activation mapping of the left atrium (①) and right atrium (②), and entrainment mapping of the left atrium (③~⑥). Activation mapping of the left atrium indicated a focal activation mode, and the earliest atrial activation was located at the anterior roof. The total activation time of the left atrium was 201 ms, less than the TCL of 252 ms. Activation mapping of the right atrium showed that the right atrium was passively activated by the left atrium. Entrainment from MI (③ and ④) produced significantly prolonged PPI (PPI-TCL = 72 ms in ③; PPI-TCL = 82 ms in ④), while entrainment from the anterior roof (⑤) and posterior inferior wall near the CS (⑥) produced short PPIs (PPI-TCL = 12 ms in ⑤; PPI-TCL = 7 ms in ⑥). (B) Entrainment from CS produced short PPIs. (C) Entrainment from VOM also produced short PPIs. The activation mapping and entrainment mapping indicated that the tachycardia was MI-dependent with an epicardial connection (VOM). (D) Selective VOM venography prolonged the TCL without terminating the tachycardia (① and ②). Injection of 2 mL of ethanol into VOM terminated the tachycardia (③). Fluoroscopic images of a VOM venogram and VOM catheter (VOMc) were shown in right anterior oblique (RAO) view (④). PVI, pulmonary vein isolation; VOM, vein of Marshall; TCL, tachycardia cycle length; MI, mitral isthmus; PPI, postpacing interval; CS, coronary sinus.
Summary of clinical studies of EIVOM in PeAF.
| Reference | Study Type | Study Population | Ablation Strategy | Primary Endpoint | N | Total Procedure Time (min) | Follow-Up Duration | Complications | Key Findings | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EIVOM | Control | EIVOM | Control | ||||||||
| Pambrun et al. 2019 [ | Single-arm | Persistent AF | EIVOM + PVI + MI line + Roof line + CTI | - | Freedom from arrhythmia recurrence | 10 | - | 270 ± 29.9 | 6 m | None | AF termination and noninducibility were achieved in 50% and 90% of the patients, respectively. All patients were free from arrhythmia recurrence during follow-up. |
| Liu et al. | Retrospective, observational | Non-paroxysmal AF | PVI + substrate modification + EIVOM | PVI + substrate modification or PVI | A recurrence of AF or any atrial arrhythmia | 32 | 64 and 32 | 125.4 ± 65.6 vs. 149.7 ± 45.9 vs. 113.4 ± 52.1 | 3.9 ± 0.5 y | - | Total atrial arrhythmia recurrence was 28.1%, 59.7%, and 44.6%, respectively. Left atrial diameter >45 mm and hypertension were independent risk factors for recurrence. |
| Valderrábano et al. 2020 [ | Multi-center randomized controlled trial | Persistent AF | Catheter ablation (sequential approach) + EIVOM | Catheter ablation alone | Freedom from AF or AT after a single procedure, without AADs, at both 6 and 12 months | 185 | 158 | 215.9 ± 77.7 vs. 190.3 ± 63.5 | 6 m and 12 m | 34/185 vs. 27/158 | Freedom from AF or tachycardia was 49.2% (91/185) vs. 38% (60/158) at 6 and 12 months after a single procedure. After multiple procedures, freedom from AF was 65.2% vs. 53.8%. |
| Nakashima et al. 2020 [ | Retrospective, observational, single-center | Persistent AF (>97%) | EIVOM + PVI+ MI ablation + additional substrate modification | PVI+ MI ablation + additional substrate modification | 12-month freedom from AF/AT/AFL | 152 | 110 | 276 ± 60 vs. 263 ± 69 | 291 ± 170 d | 2/152 vs. 1/110 | During follow-up, 31.6% (48/152) of patients in the EIVOM group and 75.5% (83/110) of patients in the RFCA group experienced recurrent AF or AT, respectively. Acute and durable MI blocks were more frequently achieved in the EIVOM group. |
| Derval et al. 2021 [ | Prospective, observational, single-arm | Persistent AF | EIVOM + PVI + MI line + Roof line + CTI | - | 12-month freedom from AF/AT without AADs | 75 | - | 277 ± 41 | 12 m | transient ischemic attack (2), postablation pericarditis (4), minor groin hematomas (3) | At 12 months, 72% (54/75) and 89% (67/75) of patients were free from AF/AT after a single procedure or 1 or 2 procedures, respectively. |
| Lai et al. 2021 [ | Prospective, observational, single-center | Persistent AF | EIVOM + PVI + MI line + Roof line + CTI | PVI + MI line + Roof line + CTI | Free from AF/AT at 12 months | 66 | 125 | 162.4 ± 39.7 vs. 171.5 ± 44.8 | 12 m | 3% vs. 5.6% | At 12 months, 58/66 (87.9%) patients in EIVOM group and 81/125 (64.8%) patients in control group were free from AF/AT, respectively. |
| Nakashima et al. 2022 [ | Retrospective, observational, single-center | Persistent AF with a previous failed ablation | EIVOM + PVI + MI line + Roof line + CTI | PVI + ablation of complex atrial | Free from AF/AT at 12 months | 96 | 102 | 222 ± 57 vs. 267 ± 93 | 12 m | 0/96 vs. 3/102 | At one-year follow-up, 21/96 (22%) patients in EIVOM group and 38/102 (37%) patients in control group had AF/AT recurrence, respectively. |
PVI, pulmonary vein isolation; EIVOM, ethanol infusion of vein of Marshall; PeAF, Persistent AF; AF, atrial fibrillation; AT, atrial tachycardia; AFL, atrial flutter; MI, mitral isthmus; CTI, cavotricuspid isthmus; AAD, anti-arrhythmic drugs.
Figure 4Fluoroscopic images in RAO view showing the procedural steps of VOM ethanol infusion. (A) Coronary sinus venography showing the presence of VOM. (B) Selective VOM venography. (C) Guidewire advanced into the VOM. (D) Balloon advanced into the VOM and inflated. (E) Selective VOM venography via the wire port of the balloon performed to confirm complete occlusion. (F) Contrast injection into VOM showing myocardial staining with the contrast medium after ethanol infusion. (G) Voltage mapping of posterior MI, left pulmonary vein-LAA ridge region, and left pulmonary veins before VOM ethanol infusion. (H) Voltage mapping in the same region showing low-voltage regions in the anatomical distribution of the VOM after VOM ethanol infusion. LAA, left atrial appendage; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; MI, mitral isthmus; MA, mitral annulus. RAO, right anterior oblique.